Vibalogics GmbH
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vibalogics GmbH - overview
Established
2002
Location
-, -, Germany
Primary Industry
Pharmaceuticals
About
Vibalogics GmbH is a biopharmaceutical company specializing in the development and manufacturing of biologics, including advanced therapies such as viral vectors and mRNA, essential for innovative medicinal solutions. Founded in 2002 and headquartered in Germany, Vibalogics GmbH focuses on biologics development and manufacturing. In February 2022, the company was fully acquired by Recipharm AB from Ampersand Capital Partners, supporting its expansion in the US and European markets. The current leadership includes Tom Hochuli as CEO, Roger Lias PhD as Chief Commercial Officer, Michael DiMeo as Chief Financial Officer, and Kai Lipinski PhD as Chief Scientific Officer.
Vibalogics GmbH provides comprehensive biologics drug development and manufacturing services, focusing on advanced therapies like mRNA, lipid nanoparticles, and viral vectors. Their offerings cater to pharmaceutical and biotech firms, supporting vaccine development, gene therapy, and treatment of infectious diseases across North America, Europe, and Asia. In 2022, Vibalogics GmbH reported a revenue of USD 9. 17 mn and an EBITDA of USD 2.
05 mn, driven by business-to-business contracts for specialized manufacturing services tailored to advanced therapy medicinal products. The acquisition by Recipharm AB in February 2022 enables Vibalogics GmbH to enhance its service offerings in novel biological modalities. The company aims to expand its presence in the US and European markets, facilitating the development of innovative products to meet growing demand. Recent funding will support these initiatives, allowing Vibalogics to broaden its capabilities in advanced biomanufacturing.
Current Investors
EQT, Recipharm AB
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.vibalogics.com
Verticals
Manufacturing
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Vibalogics GmbH - timeline of key events
Vibalogics GmbH - financials
| Fiscal Year Ended | Jun 30, 2010 | Jun 30, 2011 | Jun 30, 2012 | Jun 30, 2013 | Jun 30, 2014 | Jun 30, 2015 | Jun 30, 2016 | Jun 30, 2017 | Jun 30, 2018 | Jun 30, 2019 | Jun 30, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | - | - | - | - | - | - | - | - | - | - | 3,089,220.8 | - | - | - |
| Operating Income (USD) | - | - | - | - | - | - | - | - | - | - | 2,785,755.6 | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | 17,387.9 | 15,321.6 | 19,997.4 | 17,054.1 | 1,477,976.7 | (393,414.3) | (65,816.9) | (314,657.2) | 1,026,176 | 484,237 | 1,947,977.4 | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Vibalogics GmbH - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | Vibalogics GmbH | - | ||||||||
| Buyout | Completed | Vibalogics GmbH | - |
Displaying 1 - 2 of 2
Vibalogics GmbH - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.